Regulated information – Inside information
IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” or “MDxHealth“) a commercial-stage innovative molecular diagnostics company, announces today that it entered into a subscription agreement with MVM V LP and MVM GP (No.5) LP, funds managed by MVM Partners LLP (collectively “MVM“), pursuant to which MVM has agreed to provide an equity investment to the Company for an aggregate amount of EUR 12,738,632.94 (or approximately $14 Million).
The equity investment will consist of a subscription of 20,162,924 new ordinary shares of the Company at an issue price of EUR 0.632 per share, representing a 5% discount to the 45-day volume weighted average price. As a result of the transaction, MVM will become a 22% shareholder of the Company. The transaction is subject to limited customary conditions precedent and is expected to close on or about 15 May 2020.
The net proceeds of the capital increase will be used to support the Company’s growth strategy, as well as for general corporate purposes.
As part of the equity investment, MVM will be entitled to have one observer at the board of directors of the Company as from today and, subject to completion of the transaction, for as long as MVM will hold in aggregate 5% of the Company’s outstanding shares. In addition, the Company agreed that it will propose to the Company’s general shareholders’ meeting to appoint Eric Bednarski, PhD, as director of the Company. Kyle Dempsey, MD, shall be an observer to the board.
Michael McGarrity, CEO of MDxHealth, commented: “We are very excited to have this infusion of growth capital into MDxHealth. MVM represents the highest quality of healthcare investors. This investment marks a validation milestone for the Company and signals recognition of our value proposition in both the European and U.S. markets. On behalf of MDxHealth, we would like to welcome Eric Bednarski and MVM to our team and look forward to building value for all our stakeholders including patients, customers, employees and shareholders.”
Eric Bednarski, Partner of MVM, commented: “Prostate cancer continues to be the second leading cause of cancer death among men and there remains a great need to improve diagnosis and treatment. MDxHealth is a rare example of a company with strong leadership and best-in-class diagnostic tests which provide meaningful and necessary information to better inform physicians and patients. We are excited to partner with MDxHealth and are pleased that this funding will provide support for the growth of its ConfirmMDx and SelectMDx tests.”
Koen Hoffman, Chairman of the Board of Directors of MDxHealth commented: “On behalf of the Board of Directors, I would like to welcome Eric Bednarski and the MVM team as partners to MDxHealth. We have been very impressed with their diligence and professionalism, and we believe they bring a deep understanding of our business and will complement our Board and Management team as we build value in MDxHealth.”
The new shares to be issued will have the same rights and benefits as, and rank pari passu in all respects with, the existing and outstanding shares of the Company at the moment of their issuance and will be entitled to distributions in respect of which the relevant record date or due date falls on or after the date of issue of the new shares. The Company shall apply to Euronext Brussels for the admission to trading of the new shares as soon as practicable, and in any event within 90 days after their issuance.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
MVM has been investing in innovative, high growth healthcare businesses since 1997. MVM has a broad, global, investment remit investing in medical technology, diagnostics, and pharmaceuticals in private deals and quoted companies. In aggregate, MVM has raised investment vehicles totaling over $1 billion which are managed from offices in Boston and London.
VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023
SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]
CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition
July 14, 2023
BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]
Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023
ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]
eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023
New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]
GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023
TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]
OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023
OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]
VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023
Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]
VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023
VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]
MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022
BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]